CureDuchenne Ventures LLC, a company that funds research to find a cure for Duchenne muscular dystrophy, is investing $1 million in Capricor Therapeutics to advance promising research to treat heart disease associated with Duchenne muscular dystrophy. Capricor has shown positive pre-clinical data for Cardiosphere-derived cells (CDCs) on Duchenne muscular dystrophy cardiomyopathy. CureDuchenne is investing in Capricor to support the conduct of a first clinical trial (Phase I) in patients with Duchenne. Click here to learn more.
CureDuchenne Ventures LLC was formed by CureDuchenne, the leading nonprofit organization dedicated to improving and extending the lives of those living with Duchenne muscular dystrophy. CureDuchenne has a successful venture philanthropy model and will expand the ability to invest in translational research by offering investors an opportunity to capitalize on its expertise on Duchenne research.